M&A/Tender offer/2026/Pacira BioSciences, Inc.
Pacira BioSciences, Inc. PCRX
Viatris Inc. is buying Pacira BioSciences, Inc. (PCRX) for $36.50 cash a share. Pacira develops and commercializes pharmaceutical products including EXPAREL, a long-acting local analgesic, and ZILRETTA for osteoarthritis knee pain.
Holders get
$36.50 cash
Deal value
Not given
Expected close
Not given
Status
Pending
Checked
See the filing →
Filed
The deal
Viatris Inc. is acquiring Pacira BioSciences, Inc. (PCRX). Pacira develops and commercializes pharmaceutical products including EXPAREL, a long-acting local analgesic, and ZILRETTA for osteoarthritis knee pain. Shareholders will receive $36.50 per Share in cash.
The offer expires November 16, 2026. Closing requires HSR waiting period expiry or termination, no injunction prohibiting the transaction, minimum tender condition, and accuracy of representations and warranties.
What has happened
Agreement signed · Pacira BioSciences entered into a merger agreement with Viatris under which Purchaser will commence a tender offer at $36.50 per Share in cash. · See the filing
The board answered the offer
What must happen first
HSR waiting period expiry or termination
no injunction prohibiting the transaction
minimum tender condition
accuracy of representations and warranties
The board says
unanimously recommends that stockholders accept the Offer and tender their Shares